BioNxt Solutions Inc.
BNXTF
$0.3747
$0.0257.15%
| Weiss Ratings | BNXTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | BNXTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BNXTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.94 | |||
| Price History | BNXTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 9.37% | |||
| 30-Day Total Return | 33.96% | |||
| 60-Day Total Return | 98.25% | |||
| 90-Day Total Return | 90.01% | |||
| Year to Date Total Return | 31.24% | |||
| 1-Year Total Return | -13.78% | |||
| 2-Year Total Return | -26.28% | |||
| 3-Year Total Return | -49.84% | |||
| 5-Year Total Return | -75.83% | |||
| 52-Week High % Change | -15.93% | |||
| 52-Week Low % Change | 235.75% | |||
| Price | BNXTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.45 | |||
| 52-Week Low Price | $0.11 | |||
| 52-Week Low Price (Date) | Sep 12, 2024 | |||
| 52-Week High Price (Date) | Mar 11, 2024 | |||
| Valuation | BNXTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 44.22M | |||
| Enterprise Value | 48.06M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.04 | |||
| Earnings Per Share Growth | -55.92% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1,873.50 | |||
| Price/Book (Q) | -7.74 | |||
| Enterprise Value/Revenue (TTM) | 1,684.37 | |||
| Price | $0.37 | |||
| Enterprise Value/EBITDA (TTM) | -13.48 | |||
| Enterprise Value/EBIT | -13.23 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BNXTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 113.02M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BNXTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 780 818 6422 | |||
| Address | 1820 Fir Street Vancouver, BC V6J 3B1 | |||
| Website | www.bionxt.com | |||
| Country | Canada | |||
| Year Founded | 2017 | |||
| Profitability | BNXTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -12,735.92% | |||
| Profit Margin | -15,422.65% | |||
| Management Effectiveness | BNXTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -254.65% | |||
| Return on Equity | -- | |||
| Income Statement | BNXTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 30.90K | |||
| Total Revenue (TTM) | 30.90K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | 30.90K | |||
| EBITDA (TTM) | -3.86M | |||
| EBIT (TTM) | -3.94M | |||
| Net Income (TTM) | -4.77M | |||
| Net Income Avl. to Common (TTM) | -4.77M | |||
| Total Revenue Growth (Q YOY) | 190.70% | |||
| Earnings Growth (Q YOY) | -2.67% | |||
| EPS Diluted (TTM) | -0.04 | |||
| EPS Diluted Growth (Q YOY) | 10.38% | |||
| Balance Sheet | BNXTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 59.30K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 210.90K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -5.47M | |||
| Current Ratio (Q) | 0.035 | |||
| Book Value Per Share (Q) | -$0.05 | |||
| Total Assets (Q) | 529.70K | |||
| Total Current Liabilities (Q) | 6.00M | |||
| Total Debt (Q) | 4.16M | |||
| Total Liabilities (Q) | 6.00M | |||
| Total Common Equity (Q) | -5.47M | |||
| Cash Flow | BNXTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 201.30K | |||
| Cash from Financing (TTM) | 1.80M | |||
| Net Change in Cash (TTM) | -384.30K | |||
| Levered Free Cash Flow (TTM) | -1.31M | |||
| Cash from Operations (TTM) | -2.39M | |||
